Sharemaestro company-news research for Neurosense Therapeutics Ltd (NRSN), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest NRSN news and sentiment
Neurosense Therapeutics Ltd
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
14 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone36/100
→
Published 30-day score49/100
Latest source headline
NRSN Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 7.14% - Positive Surprise Momentum
https://www.dars.gov.et/ · 05 Oct 2026 19:32
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
14 current stories are mapped specifically to NRSN.
The score uses 3 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.061.
Confidence is 19/100, below the threshold for a firm score.
49/100
News scoreEarly balanced news score
19/100
Confidencethin evidence
100%/100
Company news14 company stories
98/100
Story agreement2/100 difference
News history
Daily score and story count over 30 days
12 Sep27 Sep11 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence1
0.061 after freshness weightingSource breadth60
3 independent publishersCompany relevance100
share tied directly to this companyFreshness16
recency-weighted evidenceAgreement98
how closely stories agreePublisher mix30
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202649USD 3.66-7.0%
02 Oct 202649USD 3.935-43.4%
25 Sep 202647USD 6.95+9.4%
18 Sep 202651USD 6.35-8.6%
11 Sep 202651USD 6.944-32.0%
04 Sep 202652USD 10.216+21.5%
28 Aug 202650USD 8.408+11.7%
21 Aug 202650USD 7.526-16.9%
Provisional evidence
News subjects
What is shaping the score
Market update509 stories · 64%
Earnings473 stories · 21%
Balance sheet371 stories · 7%
Analyst action501 stories · 7%
Source mix
Where the evidence comes from
Stock Titan384 stories · 29%
PR Newswire503 stories · 21%
Yahoo! Finance Canada502 stories · 14%
dars.gov.et321 stories · 7%
https://www.dars.gov.et/501 stories · 7%
Moomoo501 stories · 7%
MT Newswires501 stories · 7%
Recurring subjects
Subjects appearing most often
Life Sciences8Financial Markets5Finance4Earnings3Clinical Trials1Biotech1Als1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
21 Jun50 neutral11 Oct 20:16
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 11 Oct 20:16 | 50 | +1 | 19/100 (-4) | 14 (-2) | Provisional |
| 05 Oct 23:59 | 49 | +0 | 23/100 (-3) | 16 (0) | Provisional |
| 03 Oct 23:59 | 49 | +0 | 26/100 (-3) | 16 (+2) | Provisional |
| 02 Oct 23:59 | 49 | +0 | 29/100 (+1) | 14 (0) | Provisional |
| 30 Sep 23:59 | 49 | +0 | 28/100 (-1) | 14 (0) | Provisional |
| 29 Sep 23:59 | 49 | +0 | 29/100 (-2) | 14 (+2) | Provisional |
| 28 Sep 23:59 | 49 | +2 | 31/100 (+1) | 12 (+1) | Provisional |
| 25 Sep 23:59 | 47 | -1 | 30/100 (+1) | 11 (+1) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 14 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Balance sheet1 story
82.8%0.0%
Earnings1 story
17.2%0.0%
Each side uses the same scale: 0–82.8% of the retained directional evidence.
Where the influence comes from
82.8%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
EarningsNot used in direction
NRSN Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 7.14% - Positive Surprise Momentum
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 05 Oct 2026 19:32
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
NeuroSense Therapeutics Ltd. (NRSN) Stock Price, News, Quote & History
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 03 Oct 2026 21:45
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.9d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
NeuroSense Provides Update on Nasdaq Listing Compliance
NeuroSense Therapeutics announced it has received an extension from Nasdaq to meet the minimum bid price requirement. The company now has until February 18, 2027, to regain compliance, provided it meets an interim compliance requirement by August 22, 2026. NeuroSense plans to address the …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
NeuroSense Therapeutics announced it has received an extension from Nasdaq to meet the minimum bid price requirement. The company now has until February 18, 2027, to regain compliance, provided it meets an interim compliance requirement by August 22, 2026. NeuroSense plans to address the deficiency through various available options to maintain its Nasdaq listing.
- Published
- 03 Oct 2026 16:30
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 4 consolidated
AlsBiotechClinical TrialsFinanceFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Neurosense Therapeutics Receives Nasdaq Listing Compliance Notice
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 02 Oct 2026 20:36
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
The $1 bid-price hurdle is cleared, but NeuroSense (Nasdaq: NRSN) still faces delisting.
NeuroSense Therapeutics Ltd. announced that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share after a 1-for-20 reverse share split. However, the company still faces delisting as it failed to meet the $35 million minimum market value of listed securi…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
NeuroSense Therapeutics Ltd. announced that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share after a 1-for-20 reverse share split. However, the company still faces delisting as it failed to meet the $35 million minimum market value of listed securities (MVLS) requirement by September 29, 2026. NeuroSense intends to appeal this decision by requesting a hearing with the Nasdaq Hearings Panel to seek additional time to regain MVLS compliance.
- Published
- 02 Oct 2026 20:28
- News subject
- Market update
- Why this score
- Failed To Meet
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
A $35 million Nasdaq market-value rule remains unmet; NeuroSense plans to seek more time.
NeuroSense Therapeutics (NRSN) has regained compliance with Nasdaq's minimum bid price requirement but faces delisting for failing to meet the $35 million minimum market value of listed securities requirement by the September 29, 2026 deadline. The company intends to appeal this determina…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
NeuroSense Therapeutics (NRSN) has regained compliance with Nasdaq's minimum bid price requirement but faces delisting for failing to meet the $35 million minimum market value of listed securities requirement by the September 29, 2026 deadline. The company intends to appeal this determination by requesting a hearing with the Nasdaq Hearings Panel and seeking additional time to regain compliance. During the appeal process, NeuroSense's shares and warrants are expected to continue trading.
- Published
- 02 Oct 2026 04:15
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Life SciencesFinancial Markets
—Unscored
Market updateNot used in direction
NeuroSense Therapeutics (Nasdaq:NRSN) - Stock Analysis
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 30 Sep 2026 07:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.6d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
NeuroSense Therapeutics Ltd. announced that its CFO, Or Eisenberg, will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026, in New York City. He will engage in one-on-one and small-group investor meetings to discuss the company's clinical and regu…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
NeuroSense Therapeutics Ltd. announced that its CFO, Or Eisenberg, will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026, in New York City. He will engage in one-on-one and small-group investor meetings to discuss the company's clinical and regulatory progress with PrimeC, their lead drug candidate for ALS, and its strategy for regulatory approval. NeuroSense is a late-stage clinical biotechnology company developing treatments for neurodegenerative diseases, with PrimeC having shown promising results in slowing functional decline in ALS.
- Published
- 29 Sep 2026 16:35
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
FinanceLife Sciences
—Unscored
Analyst actionNot used in direction
NeuroSense Therapeutics Ltd. (NRSN) Stock Price, News, Quote & History
This article provides a detailed overview of NeuroSense Therapeutics Ltd. (NRSN), a clinical-stage biotechnology company focused on neurodegenerative diseases. It covers the company's stock performance, key financial metrics, product pipeline including PrimeC for ALS and Alzheimer's, and …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides a detailed overview of NeuroSense Therapeutics Ltd. (NRSN), a clinical-stage biotechnology company focused on neurodegenerative diseases. It covers the company's stock performance, key financial metrics, product pipeline including PrimeC for ALS and Alzheimer's, and recent analyst ratings. The stock experienced significant gains over the past year but showed a slight drop in pre-market trading.
- Published
- 29 Sep 2026 08:32
- News subject
- Analyst action
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
NeuroSense CFO will meet investors one-on-one in New York
NeuroSense Therapeutics' CFO, Or Eisenberg, will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026, meeting with institutional investors in New York City. Discussions will focus on the clinical and regulatory progress of PrimeC, their ALS drug ca…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
NeuroSense Therapeutics' CFO, Or Eisenberg, will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026, meeting with institutional investors in New York City. Discussions will focus on the clinical and regulatory progress of PrimeC, their ALS drug candidate, and the company's strategy for regulatory approval in Canada, the U.S., and other markets. This news followed a 26.62% drop in NRSN's stock price the previous day.
- Published
- 28 Sep 2026 18:58
- News subject
- Market update
- Why this score
- Regulatory Approval
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceLife Sciences
—Unscored
Market updateNot used in direction
NeuroSense Provides Business Update and Progress for the First Half of 2026
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 25 Sep 2026 20:30
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
37/100 tone
NeuroSense Therapeutics Ltd. reported a net loss of $3.563 million for the first half of 2026 and holds only $231,000 in cash, prompting a "substantial doubt" warning about its ability to continue as a going concern. The company's cash resources are insufficient to fund 12 months of opera…
82.8% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
NeuroSense Therapeutics Ltd. reported a net loss of $3.563 million for the first half of 2026 and holds only $231,000 in cash, prompting a "substantial doubt" warning about its ability to continue as a going concern. The company's cash resources are insufficient to fund 12 months of operations under its original development plan without delays. NeuroSense is pursuing additional financing and strategic alternatives while advancing its lead drug candidate, PrimeC, towards a New Drug Submission in Canada and an optimized Phase 3 trial in the U.S.
- Published
- 25 Sep 2026 20:23
- News subject
- Balance sheet
- Why this score
- Balance-sheet distress
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 46/100
- 30-day weight
- 82.8% of directional evidence · 16.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
EarningsFinanceFinancial MarketsLife Sciences
32/100 tone
17.2% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
- Published
- 20 Sep 2026 12:45
- News subject
- Earnings
- Why this score
- Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 47/100
- 30-day weight
- 17.2% of directional evidence · 21.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
NeuroSense Therapeutics will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026, in New York City. The company will discuss its clinical and regulatory progress with PrimeC, its lead drug candidate for ALS, including preparations for the Pha…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
NeuroSense Therapeutics will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026, in New York City. The company will discuss its clinical and regulatory progress with PrimeC, its lead drug candidate for ALS, including preparations for the Phase 3 PARAGON trial. NeuroSense management will also be available for one-on-one investor meetings during the conference.
- Published
- 14 Sep 2026 01:29
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 27.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
EarningsLife Sciences
Earlier company news
NRSN news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
20Sep 2026
Article detailsHistorical record
- Published
- 20 Sep 2026 13:46
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 2 consolidated
11Sep 2026
ArchivedNegative tone
NeuroSense (NASDAQ: NRSN) cuts share count to 1.9M in 1-for-20 split
NeuroSense Therapeutics is implementing a 1-for-20 reverse share split, effective September 14, 2026, on the Nasdaq Capital Market. This action will consolidate 37,938,036 ordinary shares into 1,896,902, with fractional shares rounded up and outstanding warrants/options adjusted proportio…
Article detailsHistorical record
NeuroSense Therapeutics is implementing a 1-for-20 reverse share split, effective September 14, 2026, on the Nasdaq Capital Market. This action will consolidate 37,938,036 ordinary shares into 1,896,902, with fractional shares rounded up and outstanding warrants/options adjusted proportionally. The authorized share capital remains unchanged, and a new CUSIP number (M74240207) will be issued.
- Published
- 11 Sep 2026 19:51
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
11Sep 2026
ArchivedNeutral tone
NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq
NeuroSense Therapeutics announced a 1-for-20 reverse share split for its Nasdaq-listed shares, effective September 14, 2026. This move will reduce outstanding shares from approximately 37.9 million to 1.9 million, with fractional shares rounded up and warrants/options adjusted proportiona…
Article detailsHistorical record
NeuroSense Therapeutics announced a 1-for-20 reverse share split for its Nasdaq-listed shares, effective September 14, 2026. This move will reduce outstanding shares from approximately 37.9 million to 1.9 million, with fractional shares rounded up and warrants/options adjusted proportionally. The company, which focuses on neurodegenerative disease therapies, aims to reshape its share structure to influence market positioning.
- Published
- 11 Sep 2026 19:51
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
10Sep 2026
ArchivedNeutral tone
NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq
Article detailsHistorical record
- Published
- 10 Sep 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
09Sep 2026
ArchivedNegative tone
NeuroSense (NASDAQ: NRSN) cuts share count to 1.9M in 1-for-20 split
NeuroSense Therapeutics is implementing a 1-for-20 reverse share split, effective September 14, 2026, on the Nasdaq Capital Market. This action will consolidate 37,938,036 ordinary shares into 1,896,902, with fractional shares rounded up and outstanding warrants/options adjusted proportio…
Article detailsHistorical record
NeuroSense Therapeutics is implementing a 1-for-20 reverse share split, effective September 14, 2026, on the Nasdaq Capital Market. This action will consolidate 37,938,036 ordinary shares into 1,896,902, with fractional shares rounded up and outstanding warrants/options adjusted proportionally. The authorized share capital remains unchanged, and a new CUSIP number (M74240207) will be issued.
- Published
- 9 Sep 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
04Sep 2026
NeuroSense Therapeutics has announced a revised development strategy for its ALS drug candidate, PrimeC, aimed at achieving potential regulatory approval faster and more cost-effectively. The new three-part program includes AI-enabled characterization of PrimeC's formulation, an active-co…
Article detailsHistorical record
NeuroSense Therapeutics has announced a revised development strategy for its ALS drug candidate, PrimeC, aimed at achieving potential regulatory approval faster and more cost-effectively. The new three-part program includes AI-enabled characterization of PrimeC's formulation, an active-comparator trial against edaravone, and a streamlined pivotal Phase 3 study. This strategy builds on positive Phase 2b data and seeks to provide an earlier path to market for ALS patients, with a parallel regulatory pathway being pursued in Canada.
- Published
- 4 Sep 2026 19:51
- Catalyst
- Regulatory and legal
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Life Sciences
02Sep 2026
Article detailsHistorical record
- Published
- 2 Sep 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
01Sep 2026
ArchivedNeutral tone
NRSN Q2'26 Earnings: EPS estimate is (0.20) USD
Article detailsHistorical record
- Published
- 1 Sep 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
01Sep 2026
ArchivedNeutral tone
NeuroSense Redesigns PrimeC Development Plan for ALS
NeuroSense has announced a redesigned development plan for its ALS drug, PrimeC, which aims to cut development costs by half and accelerate regulatory submission. The plan includes a comparative study against edaravone, optimized Phase 3 trial design for faster FDA approval, and a New Dru…
Article detailsHistorical record
NeuroSense has announced a redesigned development plan for its ALS drug, PrimeC, which aims to cut development costs by half and accelerate regulatory submission. The plan includes a comparative study against edaravone, optimized Phase 3 trial design for faster FDA approval, and a New Drug Submission to Health Canada planned for December 2026. These strategic moves are intended to enhance commercialization potential, attract investors, and provide earlier access for Canadian patients.
- Published
- 1 Sep 2026 03:31
- Catalyst
- Regulatory and legal
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsLife Sciences
31Aug 2026
Article detailsHistorical record
- Published
- 31 Aug 2026 13:45
- Catalyst
- Regulatory and legal
- Coverage
- Direct company
- Duplicates
- 1 consolidated
31Aug 2026
NeuroSense Therapeutics has announced an accelerated and capital-efficient strategy for its lead drug candidate, PrimeC, in ALS treatment. The new plan includes an AI-enabled characterization of PrimeC's formulation, an active-comparator trial against edaravone, and a streamlined pivotal …
Article detailsHistorical record
NeuroSense Therapeutics has announced an accelerated and capital-efficient strategy for its lead drug candidate, PrimeC, in ALS treatment. The new plan includes an AI-enabled characterization of PrimeC's formulation, an active-comparator trial against edaravone, and a streamlined pivotal Phase 3 study, aiming for faster and less costly regulatory submission. Additionally, NeuroSense is pursuing a parallel regulatory pathway in Canada to make PrimeC available sooner.
- Published
- 31 Aug 2026 09:45
- Catalyst
- Regulatory and legal
- Coverage
- Direct company
- Duplicates
- 2 consolidated
Life Sciences
25Aug 2026
ArchivedNeutral tone
NeuroSense Therapeutics Ltd. Revenue Breakdown – NASDAQ:NRSN
This article provides an overview of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) financial information on TradingView, focusing on its revenue breakdown. It indicates that the company's financial data, including segments and regional performance, is available through various sources like I…
Article detailsHistorical record
This article provides an overview of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) financial information on TradingView, focusing on its revenue breakdown. It indicates that the company's financial data, including segments and regional performance, is available through various sources like ICE Data Services, FactSet, and Quartr for SEC filings. The article is primarily a navigation hub to financial details and related tools on the TradingView platform.
- Published
- 25 Aug 2026 10:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 2 consolidated
EarningsFinancial MarketsLife Sciences
25Aug 2026
ArchivedNeutral tone
NeuroSense Therapeutics Ltd. Revenue Breakdown – NASDAQ:NRSN
This article provides an overview of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) financial information on TradingView, focusing on its revenue breakdown. It indicates that the company's financial data, including segments and regional performance, is available through various sources like I…
Article detailsHistorical record
This article provides an overview of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) financial information on TradingView, focusing on its revenue breakdown. It indicates that the company's financial data, including segments and regional performance, is available through various sources like ICE Data Services, FactSet, and Quartr for SEC filings. The article is primarily a navigation hub to financial details and related tools on the TradingView platform.
- Published
- 25 Aug 2026 10:28
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
17Aug 2026
Article detailsHistorical record
- Published
- 17 Aug 2026 20:47
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
15Aug 2026
NeuroSense Therapeutics has released a CEO letter detailing plans for its pivotal Phase 3 ALS trial of PrimeC, following FDA clearance. The company is actively pursuing various funding options for the trial and is preparing a New Drug Submission for PrimeC in Canada, targeted for December…
Article detailsHistorical record
NeuroSense Therapeutics has released a CEO letter detailing plans for its pivotal Phase 3 ALS trial of PrimeC, following FDA clearance. The company is actively pursuing various funding options for the trial and is preparing a New Drug Submission for PrimeC in Canada, targeted for December 2026. Additionally, NeuroSense is addressing Nasdaq listing deficiencies, including a potential reverse share split, while strategic partnership discussions are underway.
- Published
- 15 Aug 2026 12:41
- Catalyst
- Deals and strategy
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
14Aug 2026
NeuroSense Therapeutics has released a CEO letter detailing plans for its pivotal Phase 3 ALS trial of PrimeC, following FDA clearance. The company is actively pursuing various funding options for the trial and is preparing a New Drug Submission for PrimeC in Canada, targeted for December…
Article detailsHistorical record
NeuroSense Therapeutics has released a CEO letter detailing plans for its pivotal Phase 3 ALS trial of PrimeC, following FDA clearance. The company is actively pursuing various funding options for the trial and is preparing a New Drug Submission for PrimeC in Canada, targeted for December 2026. Additionally, NeuroSense is addressing Nasdaq listing deficiencies, including a potential reverse share split, while strategic partnership discussions are underway.
- Published
- 14 Aug 2026 16:32
- Catalyst
- Deals and strategy
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
13Aug 2026
ArchivedNeutral tone
NeuroSense Issues CEO Letter to Shareholders
Article detailsHistorical record
- Published
- 13 Aug 2026 14:30
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
13Aug 2026
NeuroSense Therapeutics has released a CEO letter detailing plans for its pivotal Phase 3 ALS trial of PrimeC, following FDA clearance. The company is actively pursuing various funding options for the trial and is preparing a New Drug Submission for PrimeC in Canada, targeted for December…
Article detailsHistorical record
NeuroSense Therapeutics has released a CEO letter detailing plans for its pivotal Phase 3 ALS trial of PrimeC, following FDA clearance. The company is actively pursuing various funding options for the trial and is preparing a New Drug Submission for PrimeC in Canada, targeted for December 2026. Additionally, NeuroSense is addressing Nasdaq listing deficiencies, including a potential reverse share split, while strategic partnership discussions are underway.
- Published
- 13 Aug 2026 08:00
- Catalyst
- Deals and strategy
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
10Aug 2026
Article detailsHistorical record
- Published
- 10 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
10Aug 2026
Article detailsHistorical record
- Published
- 10 Aug 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
06Aug 2026
NeuroSense Therapeutics announced it has completed the Pre-NDS process with Health Canada for PrimeC, its lead therapeutic candidate for ALS, and is targeting a New Drug Submission (NDS) filing in December 2026. This follows alignment with Health Canada on the submission's content and str…
Article detailsHistorical record
NeuroSense Therapeutics announced it has completed the Pre-NDS process with Health Canada for PrimeC, its lead therapeutic candidate for ALS, and is targeting a New Drug Submission (NDS) filing in December 2026. This follows alignment with Health Canada on the submission's content and structure. The company views Canada as a significant market for PrimeC, aiming to bring a promising new treatment to ALS patients, who currently have limited options.
- Published
- 6 Aug 2026 16:11
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Life Sciences
06Aug 2026
NeuroSense Therapeutics is targeting December 2026 for filing a New Drug Submission (NDS) with Health Canada for PrimeC, its lead therapeutic candidate for ALS, following successful completion of the Pre-NDS process. This filing aligns with Health Canada's guidance and aims to bring a muc…
Article detailsHistorical record
NeuroSense Therapeutics is targeting December 2026 for filing a New Drug Submission (NDS) with Health Canada for PrimeC, its lead therapeutic candidate for ALS, following successful completion of the Pre-NDS process. This filing aligns with Health Canada's guidance and aims to bring a much-needed therapy to over 3,000 Canadians living with ALS. The NDS will be supported by strong clinical evidence from the Phase 2b PARADIGM program, demonstrating significant survival benefits and a favorable safety profile.
- Published
- 6 Aug 2026 12:29
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 3 consolidated
Life Sciences
04Aug 2026
Article detailsHistorical record
- Published
- 4 Aug 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
02Aug 2026
Article detailsHistorical record
- Published
- 2 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
01Aug 2026
ArchivedNegative tone
NeuroSense Therapeutics (NRSN) seeks reverse split amid Nasdaq compliance push
NeuroSense Therapeutics (NRSN) is calling a Special Meeting of Shareholders on August 26, 2026, to seek approval for a reverse stock split. This move is aimed at regaining compliance with Nasdaq's minimum bid price ($1.00) and market value of listed securities ($35 million) requirements, …
Article detailsHistorical record
NeuroSense Therapeutics (NRSN) is calling a Special Meeting of Shareholders on August 26, 2026, to seek approval for a reverse stock split. This move is aimed at regaining compliance with Nasdaq's minimum bid price ($1.00) and market value of listed securities ($35 million) requirements, which the company failed to meet, risking delisting by September 29, 2026. The proposed reverse split ratio ranges from 1-for-4 to 1-for-40, giving the Board flexibility to adjust the share price and maintain its Nasdaq listing.
- Published
- 1 Aug 2026 03:40
- Catalyst
- Regulatory and legal
- Coverage
- Direct company
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
01Aug 2026
ArchivedNeutral tone
NeuroSense Therapeutics (NRSN) revises Capital on Demand share sales deal
NeuroSense Therapeutics has amended its Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, updating the referenced registration statement to a new Form F-3 (File No. 333-293060), which became effective on July 31, 2026. Under the revised agreement, the company…
Article detailsHistorical record
NeuroSense Therapeutics has amended its Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, updating the referenced registration statement to a new Form F-3 (File No. 333-293060), which became effective on July 31, 2026. Under the revised agreement, the company can offer and sell ordinary shares with an aggregate offering price of up to $3,789,822. As of July 31, 2026, NeuroSense had already sold 6,762,825 ordinary shares, generating net proceeds of approximately $6.7 million through the original agreement.
- Published
- 1 Aug 2026 03:40
- Catalyst
- Deals and strategy
- Coverage
- Direct company
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
31Jul 2026
ArchivedNeutral tone
NeuroSense Therapeutics Ltd. Revenue Breakdown – NASDAQ:NRSNW
This article provides a brief overview of NeuroSense Therapeutics Ltd. (NASDAQ: NRSNW) financial information. It indicates that the market was closed at the time of viewing and that no trades were made, with details on financial statements, dividends, earnings, and segments available for …
Article detailsHistorical record
This article provides a brief overview of NeuroSense Therapeutics Ltd. (NASDAQ: NRSNW) financial information. It indicates that the market was closed at the time of viewing and that no trades were made, with details on financial statements, dividends, earnings, and segments available for further research.
- Published
- 31 Jul 2026 03:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
30Jul 2026
ArchivedNegative tone
NeuroSense Therapeutics (NRSN) sets $150M shelf and $3.8M ATM share plan
NeuroSense Therapeutics has filed a shelf registration to offer up to $150 million in various securities and a related at-the-market (ATM) program for up to $3.8 million in ordinary shares. The company, focused on neurodegenerative diseases like ALS, reported positive Phase 2b data for it…
Article detailsHistorical record
NeuroSense Therapeutics has filed a shelf registration to offer up to $150 million in various securities and a related at-the-market (ATM) program for up to $3.8 million in ordinary shares. The company, focused on neurodegenerative diseases like ALS, reported positive Phase 2b data for its lead candidate PrimeC but faces a "going concern" risk due to recurring losses and negative cash flow. The filing indicates that while these plans provide capital-raising capacity, future share sales could dilute current holders.
- Published
- 30 Jul 2026 21:09
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
FinanceLife Sciences
29Jul 2026
ArchivedNeutral tone
Price to earnings forward of NeuroSense Therapeutics Ltd. – BOATS:NRSNW
This article provides a brief snapshot of the "Price to earnings forward" metric for NeuroSense Therapeutics Ltd. (NRSNW) as listed on the Blue Ocean Alternative Trade System (BOATS). It notes that there are no current trades and displays the period, value, and change for this financial m…
Article detailsHistorical record
This article provides a brief snapshot of the "Price to earnings forward" metric for NeuroSense Therapeutics Ltd. (NRSNW) as listed on the Blue Ocean Alternative Trade System (BOATS). It notes that there are no current trades and displays the period, value, and change for this financial metric, indicating the stock market appears closed.
- Published
- 29 Jul 2026 01:11
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
28Jul 2026
ArchivedNeutral tone
Neurosense Therapeutics is a buy, this analyst says
Roth Capital Partners analyst Boobalan Pachaiyappan has reaffirmed his "Buy" rating and $3.00 price target for Neurosense Therapeutics (NASDAQ:NRSN), citing reduced regulatory uncertainty for its ALS drug candidate, PrimeC, in Canada. Despite a recent stock dip, the company has aligned wi…
Article detailsHistorical record
Roth Capital Partners analyst Boobalan Pachaiyappan has reaffirmed his "Buy" rating and $3.00 price target for Neurosense Therapeutics (NASDAQ:NRSN), citing reduced regulatory uncertainty for its ALS drug candidate, PrimeC, in Canada. Despite a recent stock dip, the company has aligned with Health Canada for a New Drug Submission pathway, potentially leading to approval in the second half of 2027. However, financing for future phases and commercialization remains a concern for investors.
- Published
- 28 Jul 2026 16:41
- Catalyst
- Analyst action
- Coverage
- Direct company
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
Provider matches checked
Provider mentions not used in the score
A news provider linked these stories to NRSN, but the headline and available text are not mainly about Neurosense Therapeutics Ltd. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of NRSN sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.